Generic versions of CSL’s iron replacement therapy Venofer have arrived in the U.S. after Viatris had initially touted a potential launch in 2022. More: CSL's Venofer finally faces generic competition as FDA clears copycats from Viatris, Sandoz and Amphastar Source:
read moreThe National Advertising Division has sided with Genomic Health in a challenge the Exact Sciences subsidiary brought against fellow cancer diagnostics maker Agendia. More: Exact’s Genomic Health puts rival Agendia in ad watchdog’s crosshairs over LinkedIn posts Source: fierce
read moreVor Bio’s big bet on RemeGen’s autoimmune asset telitacicept appears well placed after the drug—already approved across three conditions overseas—delivered a late-stage win in a Sjögren’s syndrome trial in China. More: RemeGen's telitacicept meets the mark in ph. 3 Sjögren's
read moreMerck has begun the 8% reduction of its workforce—an initiative that the company revealed two weeks ago—with the dismissal of 58 employees at its headquarters in Rahway, New Jersey. More: Merck begins 8% workforce purge, laying off 58 at its
read more
Teva’s CGRP therapy becomes first approved option for children and adolescent More: FDA approves AJOVY for paediatric migraine prevention Source: News
read more
Promising results support global submissions and priority review by US FDA More: Genmab’s epcoritamab combination meets key endpoints in phase 3 lymphoma trial Source: News
read more© 1994 - 2026 B.M. Pharmaceuticals